PT-141 and the melanocortin system: A different kind of peptide story

PT-141 started as a sunless-tanning accident. Palatin was developing a melanocortin peptide for pigmentation; people in the trials reported desire instead. The analog — bremelanotide — was aimed at melanocortin-4 receptors in the brain rather than the skin. On June 21, 2019, FDA approved it as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That is a labeled, on-demand subcutaneous drug — and a vivid reminder that receptor biology can travel in unexpected directions.

What the RECONNECT trials found

Two identical 24-week, randomized, double-blind, placebo-controlled trials enrolled 1,247 premenopausal women. Bremelanotide 1.75 mg was taken as needed, at least 45 minutes before anticipated sexual activity. Desire scores on the FSFI desire domain rose; distress on FSDS-DAO question 13 fell; both changes beat placebo. About 25% of treated patients had a desire-score jump of 1.2 or more, versus about 17% on placebo. Nausea hit about 40%. Flushing, injection-site reactions, and headache followed. The label tells patients to stop after eight weeks if nothing moves, and not to stack doses. Modest effect size. Real adverse events. A real autoinjector.

Melanocortin-4 is a receptor. Vyleesi is a product. PT-141 in a research vial is a chemical with a research nickname.

A lyophilized PT-141 lot is a different object from Vyleesi. It is not indicated for HSDD, and it has not been through RECONNECT. Inspired Labs lists it as a melanocortin research chemical because the receptor biology is real and the approved-drug story is easy to borrow casually. This journal will name the receptor, the trials, and the product — and keep the cake in the vial distinct from the autoinjector. If you are comparing lots, open PT-141 in the live catalog and keep the indication attached to the label it actually lives on.